Logo image of CTX.CA

CRESCITA THERAPEUTICS INC (CTX.CA) Stock Price, Forecast & Analysis

Canada - Toronto Stock Exchange - TSX:CTX - CA2258471028 - Common Stock

0.445 CAD
-0.01 (-1.11%)
Last: 12/9/2025, 7:00:00 PM

CTX.CA Key Statistics, Chart & Performance

Key Statistics
Market Cap8.28M
Revenue(TTM)22.07M
Net Income(TTM)457.00K
Shares18.61M
Float16.20M
52 Week High0.61
52 Week Low0.4
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)0.02
PE22.25
Fwd PEN/A
Earnings (Next)03-16 2026-03-16
IPO2016-03-07
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


CTX.CA short term performance overview.The bars show the price performance of CTX.CA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -2 -4 -6 -8 -10

CTX.CA long term performance overview.The bars show the price performance of CTX.CA in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30

The current stock price of CTX.CA is 0.445 CAD. In the past month the price increased by 1.14%. In the past year, price decreased by -23.28%.

CRESCITA THERAPEUTICS INC / CTX Daily stock chart

CTX.CA Latest News, Press Relases and Analysis

a month ago - By: Crescita Therapeutics Inc.
4 months ago - By: Crescita Therapeutics Inc. - Mentions: OTC
7 months ago - By: Crescita Therapeutics Inc. - Mentions: OTC
9 months ago - By: Crescita Therapeutics - Mentions: OTC
a year ago - By: Crescita Therapeutics - Mentions: OTC
a year ago - By: Crescita Therapeutics - Mentions: OTC

CTX.CA Competitors/Peers

The largest stocks on the Canadian markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
BHC.CA BAUSCH HEALTH COS INC 1.78 3.50B
CRON.CA CRONOS GROUP INC 24.67 1.42B
TLRY.CA TILRAY BRANDS INC N/A 1.30B
DHT-UN.CA DRI HEALTHCARE TRUST 7.34 909.87M
DHT-U.CA DRI HEALTHCARE TRUST 5.26 652.50M
GUD.CA KNIGHT THERAPEUTICS INC N/A 587.80M
WEED.CA CANOPY GROWTH CORP N/A 578.48M
NGEN.CA NERVGEN PHARMA CORP N/A 437.68M
CPH.CA CIPHER PHARMACEUTICALS INC 15.89 366.85M
ACB.CA AURORA CANNABIS INC N/A 356.43M
OGI.CA ORGANIGRAM GLOBAL INC N/A 302.24M
HITI.CA HIGH TIDE INC N/A 301.88M

About CTX.CA

Company Profile

CTX logo image Crescita Therapeutics, Inc. engages in the provision of non-prescription skincare products. The company is headquartered in Laval, Quebec and currently employs 75 full-time employees. The company went IPO on 2016-03-07. The company offers a portfolio of science-based non-prescription skincare products and early to commercial stage prescription products. The company operates in three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The Commercial Skincare segment manufactures and sells branded non-prescription skincare products for the Canadian and international markets. The company also commercializes Pliaglis, NCTF Boost 135 HA, ART FILLER, and Obagi Medical in Canada. The Licensing and Royalties segment engaged in licensing the intellectual property related to Pliaglis or its transdermal delivery technologies. Manufacturing and Services segment engaged in the sale of topical products manufactured to client specifications under the Company’s contract development and manufacturing organization infrastructure, and product development services.

Company Info

CRESCITA THERAPEUTICS INC

2805, Place Louis R Renaud

Laval QUEBEC H7V 0A3 CA

CEO: Serge Verreault

Employees: 75

CTX Company Website

CTX Investor Relations

Phone: 18003610352

CRESCITA THERAPEUTICS INC / CTX.CA FAQ

What does CRESCITA THERAPEUTICS INC do?

Crescita Therapeutics, Inc. engages in the provision of non-prescription skincare products. The company is headquartered in Laval, Quebec and currently employs 75 full-time employees. The company went IPO on 2016-03-07. The company offers a portfolio of science-based non-prescription skincare products and early to commercial stage prescription products. The company operates in three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The Commercial Skincare segment manufactures and sells branded non-prescription skincare products for the Canadian and international markets. The company also commercializes Pliaglis, NCTF Boost 135 HA, ART FILLER, and Obagi Medical in Canada. The Licensing and Royalties segment engaged in licensing the intellectual property related to Pliaglis or its transdermal delivery technologies. Manufacturing and Services segment engaged in the sale of topical products manufactured to client specifications under the Company’s contract development and manufacturing organization infrastructure, and product development services.


Can you provide the latest stock price for CRESCITA THERAPEUTICS INC?

The current stock price of CTX.CA is 0.445 CAD. The price decreased by -1.11% in the last trading session.


Does CRESCITA THERAPEUTICS INC pay dividends?

CTX.CA does not pay a dividend.


What is the ChartMill technical and fundamental rating of CTX stock?

CTX.CA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


Can you provide the number of employees for CRESCITA THERAPEUTICS INC?

CRESCITA THERAPEUTICS INC (CTX.CA) currently has 75 employees.


Can you provide the upcoming earnings date for CRESCITA THERAPEUTICS INC?

CRESCITA THERAPEUTICS INC (CTX.CA) will report earnings on 2026-03-16.


CTX.CA Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to CTX.CA. When comparing the yearly performance of all stocks, CTX.CA is a bad performer in the overall market: 87.14% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CTX.CA Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to CTX.CA. No worries on liquidiy or solvency for CTX.CA as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CTX.CA Financial Highlights

Over the last trailing twelve months CTX.CA reported a non-GAAP Earnings per Share(EPS) of 0.02. The EPS increased by 117.32% compared to the year before.


Industry RankSector Rank
PM (TTM) 2.07%
ROA 2.13%
ROE 2.81%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%174.35%
Sales Q2Q%50.06%
EPS 1Y (TTM)117.32%
Revenue 1Y (TTM)26.79%

CTX.CA Forecast & Estimates


Analysts
Analysts0
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

CTX.CA Ownership

Ownership
Inst OwnersN/A
Ins Owners12.94%
Short Float %N/A
Short RatioN/A